New weight loss shot TE-8105 tested in early human trial
NCT ID NCT06471530
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new drug called TE-8105 in 38 overweight or obese adults without diabetes. The main goal was to see if the drug is safe and how the body processes it. Participants received one or more injections of TE-8105 at different doses. The study is complete, but results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TE-8105
What this could lead to
If it works, this could point toward a new treatment for weight loss in people who are overweight or obese.
What could go wrong
This is a very early, first-in-human trial with only 38 participants. It is designed mainly to check safety and dosing, not to prove weight loss works. Many early-stage drugs fail to show benefit in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CMAX Clinical Research
Adelaide, South Australia, 5000, Australia